
ACE-031
ACE-031 (Ramatercept)
Also called ACE-031, ramatercept, ActRIIB-Fc
A myostatin trap built from its own receptor
ACE-031 was a pharmaceutical attempt at removing the brake on muscle growth, developed for Duchenne muscular dystrophy. In trials, muscle measures improved. The programme was stopped because the receptor pathway it blocks is also involved in blood vessels, and participants developed nosebleeds and visible spidery vessels on the skin.
A soluble decoy version of the activin receptor type IIB (ActRIIB). It circulates and binds myostatin and related growth-limiting signals before they can reach muscle. It reached human trials in Duchenne muscular dystrophy and was discontinued over bleeding and blood-vessel side effects. It is not an approved medicine.
- Route studied
- Subcutaneous injection (trials)
- Status
- Not FDA-approved
Human trials published, with more underway
What ACE-031 has been studied for
The reasons people look it up, roughly in order of how often, and what research exists for each. Interest in a use is not evidence that it works; the evidence is stated under each one.
- Muscle growth
- Its mechanism: it soaks up the signals that tell muscle to stop growing rather than telling it to grow. Muscle gains were measured in trials before the programme stopped.
- Muscular dystrophy
- Its actual development programme, in boys with Duchenne. It reached Phase 2 before being halted.
Mechanism of Action
How ACE-031 works
ACE-031 is a soluble decoy receptor that sequesters growth inhibitors:
- ActRIIB decoy. A soluble form of the activin receptor IIB that binds myostatin and activin in circulation before they reach the real receptor on muscle.
- Broad trapping. It binds several TGF-beta-family signals at once, not only myostatin, including one involved in blood vessel maintenance.
- Muscle growth. With these signals neutralised, muscle growth faces less restraint.
- Safety ceiling. Human trials were stopped after bleeding and blood-vessel signals (nosebleeds, gum bleeding, telangiectasias), reflecting the pathway's role beyond muscle.
ACE-031 side effects: what studies reported
This one has a documented reason it was discontinued, which puts it in a different category from compounds that simply lack data. The trial was stopped over the side effects, not over the results.
What was seen in trials
- Nosebleeds
- Small spidery blood vessels visible on the skin
- Gum bleeding
- Injection-site reactions
- Headache
Why it stopped
- The receptor it blocks is also involved in how blood vessels form and behave. The bleeding was consistent enough across participants that the programme was halted rather than adjusted
Source: Phase 2 trials in Duchenne muscular dystrophy, halted 2013. This is a summary of published findings, not a complete safety profile and not medical advice. Questions about ACE-031 belong with a licensed clinician who knows your history.
Your Genetics & ACE-031
The genes involved in how ACE-031 works
ACE-031 works through the receptors these genes build, and the genes vary from person to person. Researchers have linked some of that variation to differences in how people respond. A DNA report tells you which versions you carry.
The K153R variant in the myostatin gene has been studied for association with muscle traits, with mixed results. No study has tested whether it changes response to ACE-031.
ACTN3 · ••
The R577X variant determines whether alpha-actinin-3 is made in fast-twitch fibres, and is associated with sprint and power performance in athlete studies. Not studied with ACE-031.
This promoter variant has been associated with baseline IGF-1 levels in population studies. Pathway context only.
VDR · ••
The FokI variant in the vitamin D receptor has been studied for association with muscle strength, with mixed results. Pathway context only.
The dots after each gene are where your own result goes. Your report fills them in with the two letters you carry at that position.
Which of these variants do you carry?
Your report reads the DNA file you already have against this research.
Often discussed alongside
Compounds that come up next to ACE-031 in research and discussion. Each has its own page. None of this is a suggestion to combine them.

Follistatin-344
also blocks myostatinEmerging EvidenceFollistatin-344 (FST-344)
A naturally occurring protein that binds and neutralises myostatin and activin, the body's built-in limiters on muscle growth. Interest in it comes from preclinical and gene-therapy research on muscle; no human trial has tested injected follistatin, and it is not an approved medicine.
4
Gene variants
20+
Studies

Bimagrumab
blocks the same receptor familyEmerging EvidenceBimagrumab (Anti-ActRII Monoclonal Antibody)
Most weight drugs reduce appetite. Bimagrumab does something different: it blocks a signal that stops muscle growing past a point. In a phase 2 trial, participants lost about a fifth of their body fat while gaining lean mass, the opposite of what usually happens with weight loss. It is an antibody given by intravenous infusion in trials, and it is not approved.
3
Gene variants
15+
Studies
Access
Access and legal status
ACE-031 is not an FDA-approved drug. Products sold online as “research chemicals” are labelled not for human use, and FDA treats them as unapproved drugs when they are marketed for people. We don't link to any seller, and nothing on this page is a recommendation to obtain or use it.
Your DNA and ACE-031: see which of the variants studied alongside it you carry, and what that research does and does not show. Read my DNA, $99 →
Educational information only, not medical advice. Most peptides are not FDA-approved. Do not start, stop or change any medication or peptide because of this page; talk to a licensed clinician.
Worth knowing about ACE-031
Interactions and situations where there is a specific reason to be careful. Where the honest answer is that nobody has studied something, it says so and says what that leaves open.
- It was stopped for safety, not for failing to work
- Worth being precise about. It produced muscle gain in trials and was stopped anyway because of the bleeding and blood-vessel effects.
- The bleeding effects are the known outcome, not a theory
- These were observed in a monitored clinical trial, which is more than can be said for most safety claims about compounds in this space.
Last updated
Frequently Asked Questions
How is ACE-031 different from Follistatin-344?
Both reduce myostatin signaling but in different ways. Follistatin-344 binds the myostatin ligand directly. ACE-031 is a decoy version of the myostatin receptor (ActRIIB) that traps myostatin and related ligands before they reach muscle. ACE-031 traps a broader set of inhibitors, which is also why its safety profile is more complex.
Why was ACE-031 discontinued?
Human trials in Duchenne muscular dystrophy were halted after bleeding and blood-vessel signals (nosebleeds, gum bleeding and small dilated blood vessels), likely reflecting the pathway's roles outside muscle. It never reached approval.
Do genes affect ACE-031 response?
No study has tested whether any genotype changes response to ACE-031. MSTN, ACTN3, IGF1 and VDR variants have been associated with muscle traits in human studies, often with mixed results. A DNA report can show which versions you carry and what that research does and does not show.
Your DNA and ACE-031
What the research says about your variants.
The report
Which ACE-031 variants do you carry?
Your report reads the DNA file you already have against the published research on 31 peptides, marker by marker, and says what that research does and does not show.
Read my DNA, $99